Convergent Calling: An Interview with Medtronic's Stephen Oesterle

Historic walls between the medical device and biotech sectors are coming down as medical devices incorporate more biologically-active agents as part of their therapy. That's good news for device companies since device technology in these combination devices is every bit as critical to their clinical success as the biologic.

More from Archive

More from In Vivo